Unknown

Dataset Information

0

Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells.


ABSTRACT: Adoptive immunotherapy retargeting T cells to CD19 via a chimeric antigen receptor (CAR) is an investigational treatment capable of inducing complete tumor regression of B-cell malignancies when there is sustained survival of infused cells. T-memory stem cells (TSCM) retain superior potential for long-lived persistence, but challenges exist in manufacturing this T-cell subset because they are rare among circulating lymphocytes. We report a clinically relevant approach to generating CAR+ T cells with preserved TSCM potential using the Sleeping Beauty platform. Because IL-15 is fundamental to T-cell memory, we incorporated its costimulatory properties by coexpressing CAR with a membrane-bound chimeric IL-15 (mbIL15). The mbIL15-CAR T cells signaled through signal transducer and activator of transcription 5 to yield improved T-cell persistence independent of CAR signaling, without apparent autonomous growth or transformation, and achieved potent rejection of CD19+ leukemia. Long-lived T cells were CD45ROnegCCR7+CD95+, phenotypically most similar to TSCM, and possessed a memory-like transcriptional profile. Overall, these results demonstrate that CAR+ T cells can develop long-term persistence with a memory stem-cell phenotype sustained by signaling through mbIL15. This observation warrants evaluation in clinical trials.

SUBMITTER: Hurton LV 

PROVIDER: S-EPMC5137758 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells.

Hurton Lenka V LV   Singh Harjeet H   Najjar Amer M AM   Switzer Kirsten C KC   Mi Tiejuan T   Maiti Sourindra S   Olivares Simon S   Rabinovich Brian B   Huls Helen H   Forget Marie-Andrée MA   Datar Vrushali V   Kebriaei Partow P   Lee Dean A DA   Champlin Richard E RE   Cooper Laurence J N LJ  

Proceedings of the National Academy of Sciences of the United States of America 20161114 48


Adoptive immunotherapy retargeting T cells to CD19 via a chimeric antigen receptor (CAR) is an investigational treatment capable of inducing complete tumor regression of B-cell malignancies when there is sustained survival of infused cells. T-memory stem cells (T<sub>SCM</sub>) retain superior potential for long-lived persistence, but challenges exist in manufacturing this T-cell subset because they are rare among circulating lymphocytes. We report a clinically relevant approach to generating CA  ...[more]

Similar Datasets

| S-EPMC6329954 | biostudies-literature
| S-EPMC9280705 | biostudies-literature
| S-EPMC7873057 | biostudies-literature
| S-EPMC5705392 | biostudies-literature
| S-EPMC524066 | biostudies-literature
| S-EPMC2118539 | biostudies-literature
| S-EPMC4573903 | biostudies-literature
| S-EPMC5663359 | biostudies-literature
| S-EPMC4570106 | biostudies-literature
| S-EPMC9095767 | biostudies-literature